TG4001 with avelumab was also shown to induce a shift to an immune-hot tumour gene signature with an increase of CD8+ infiltration, a decrease of infiltrated Tregs/CD8+ ratio as well as an increase in the proportion of PD-L1+ cells in low to moderate PD-L1 expressing tumours [556]. This evidence concerns the gene CD8A and neoplasm.